Boothbay Fund Management’s NextCure NXTC Stock Holding History

Boothbay Fund Management’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$135K	Buy	84,687 +15,070	+22%	+$111K	﹤0.01%	2004
2026 Q1	$744K	Hold	69,617	–	–	0.01%	1118
2025 Q4	$988K	Buy	+69,617	New	+$721K	0.01%	808
2022 Q2	–	Sell	-1,123	Closed	-$65K	–	2547
2022 Q1	$65K	Hold	1,123	–	–	﹤0.01%	2152
2021 Q4	$81K	Sell	1,123 -3,140	-74%	-$263K	﹤0.01%	1736
2021 Q3	$345K	Sell	4,263 -1,050	-20%	-$92.1K	0.01%	1261
2021 Q2	$512K	Buy	5,313 +1,006	+23%	+$103K	0.02%	990
2021 Q1	$517K	Buy	4,307 +2,391	+125%	+$346K	0.02%	931
2020 Q4	$251K	Hold	1,916	–	–	0.01%	1017
2020 Q3	$202K	Buy	+1,916	New	+$236K	0.01%	944

Other funds holding NXTC

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Verdad Advisers Boston, Massachusetts $104M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Boothbay Fund Management's NXTC Position: Q2 2026 in Review

Boothbay Fund Management increased its NextCure (NXTC) stake by 22% in Q2 2026, buying an estimated $111K and bringing the position to 84,687 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Boothbay Fund Management first reported a position in NXTC in Q3 2020 and has held it in 10 quarters since. The position peaked at $988K in Q4 2025. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Boothbay Fund Management held 84,687 shares of NextCure worth $135K as of Q2 2026.
Boothbay Fund Management bought 15,070 NextCure shares in Q2 2026, an estimated $111K.
NextCure made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2004 holding.
Boothbay Fund Management first reported a position in NextCure in Q3 2020 and has held it in 10 quarters since.
Boothbay Fund Management's NextCure position peaked at $988K in Q4 2025.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.